Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Additionally we are shipping CD79b Molecule, Immunoglobulin-Associated beta Antibodies (363) and CD79b Molecule, Immunoglobulin-Associated beta Kits (3) and many more products for this protein.
Showing 10 out of 18 products:
Mouse (Murine) CD79B Protein expressed in Human Cells - ABIN2008278
Wood, Thompson, Korenberg, Chen, May, Wall, Denny: Isolation and chromosomal mapping of the human immunoglobulin-associated B29 gene (IGB). in Genomics 1993
Show all 6 references for ABIN2008278
Rat (Rattus) CD79B Protein expressed in Human Cells - ABIN2009490
Hashimoto, Chiorazzi, Gregersen: The complete sequence of the human CD79b (Ig beta/B29) gene: identification of a conserved exon/intron organization, immunoglobulin-like regulatory regions, and allelic polymorphism. in Immunogenetics 1994
Show all 6 references for ABIN2009490
Human CD79B Protein expressed in HEK-293 Cells - ABIN2180837
Radaev, Zou, Tolar, Nguyen, Nguyen, Krueger, Stutzman, Pierce, Sun: Structural and functional studies of Igalphabeta and its assembly with the B cell antigen receptor. in Structure (London, England : 1993) 2010
Show all 5 references for ABIN2180837
Human CD79B Protein expressed in Escherichia coli (E. coli) - ABIN1098714
Naylor, Tang, Ratsch, Enns, Loo, Chen, Lenz, Waters, Schuler, Dörken, Yao, Warmuth, Lenz, Stegmeier: Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. in Cancer research 2011
B-cell inhibition by cross-linking CD79b (show PDPK1 Proteins) is superior to B (show TDO2 Proteins)-cell depletion with anti-CD20 (show MS4A1 Proteins) antibodies in treating murine collagen-induced arthritis.
Data indicate that in the absence of DGKzeta (show DGKZ Proteins), the threshold for B cell antigen receptor (BCR (show BCR Proteins)) signaling, measured as activation of the Ras-extracellular signal-regulated kinase (ERK (show EPHB2 Proteins)) pathway, was markedly reduced in mature follicular B cells.
The cytoplasmic tail of IgG1 is strictly required for the surface expression of IgG1 when the expression of Iga/Igb heterodimer is down-regulated in B lymphoma.
endocytosed BCR (show BCR Proteins) sequentially regulates MAPK (show MAPK1 Proteins) and Akt (show AKT1 Proteins) signaling pathways from intracellular compartments
Spontaneous mutation in the Cd79b (show PDPK1 Proteins) gene leads to a block in B-lymphocyte (show AKAP17A Proteins) development at the C' (early pre-B) stage
The VHDJH recombination process at the IgH locus and the survival of pro-B cells that carry these rearrangements do not depend on the expression of Ig-beta molecules.
Deletion in developing B cells leads to cell death; Igbeta expression is essential to maintain preB (show PREB Proteins) cell and immature B cell survival and to mediate B cell differentiation
MHC II structural requirements for mediation of cell death signaling in a murine B cell lymphoma with Igalpha/beta
hotspot mutations of CD79B Y196 and MYD88 (show MYD88 Proteins) L265 may serve as a genetic hallmark for primary central nervous system lymphoma
CD79B overexpression leading to activation of AKT (show AKT1 Proteins)/MAPK (show MAPK1 Proteins) is a potential mechanism underlying primary ibrutinib resistance in ABC (show ABCB6 Proteins)-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib.
Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected.
MYD88 (show MYD88 Proteins) L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma.
Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system.
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 (show MYD88 Proteins) and CD79B mutations.
Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies.
Phosphorylation of CD79a (show CD79A Proteins) causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part.
results suggest that MYD88 (show MYD88 Proteins) mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL (show PNLIP Proteins)
CD79B and MYD88 (show MYD88 Proteins) mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease.
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described.
B-cell antigen receptor complex-associated protein beta chain
, B-cell-specific glycoprotein B29
, immunoglobulin-associated B29 protein
, immunoglobulin-associated beta
, CD79b antigen (immunoglobulin-associated beta)
, CD79B antigen